Skip to content

ANI Pharmaceuticals ANIP Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
ALN
Alnylam PharmaceuticalsALNY
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
Amgen logo
AmgenAMGN
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's accrued liabilities, current?
ANI Pharmaceuticals (ANIP) reported accrued liabilities, current of $13.74M in Q1 2026.
How has ANI Pharmaceuticals's accrued liabilities, current changed year-over-year?
ANI Pharmaceuticals's accrued liabilities, current increased by 14.2% year-over-year, from $12.03M to $13.74M.
What is the long-term trend for ANI Pharmaceuticals's accrued liabilities, current?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued liabilities, current has grown at a 47.2% compound annual growth rate (CAGR), from $2.46M to $16.97M.